Halozyme Therapeutics reported $248.25M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.91B 2.31B Sep/2025
Baxter International USD 462M 137M Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MannKind USD 9.75M 17.66M Jun/2025
Pfizer USD 6.08B 351M Sep/2025
United Therapeutics USD 436.8M 34.2M Jun/2025